In contrast, clinicians’ perceptions of PSMA PET remain largely restricted to their role in staging PCa rather than their implications for guiding RLT treatment decisions, possibly limiting the clinical use of [177Lu]Lu-PSMA-617/analogues for eligible patients. Here, FOLH1 is linked to posterior cortical atrophy.